PATAS
Type 2 Diabetes, Insulin Resistance, and Associated Comorbidities (e.g., liver steatosis/fibrosis)
Key Facts
About AdipoPharma
AdipoPharma is a clinical-stage biotechnology company pioneering a new class of metabolic therapy with its lead candidate, PATAS, a stapled peptide targeting adipocyte dysfunction. The company's science is derived from founder Dr. Vincent Marion's genetic research, which identified therapeutic targets within the adipocyte's role in lipid homeostasis and insulin resistance. PATAS aims to restore healthy lipid biosynthesis, reduce toxic ceramides, and improve complications like liver steatosis and cardiovascular risk. The program is advancing towards Phase 1 clinical trials, targeting the massive and growing global type 2 diabetes market with a potentially disease-modifying approach.
View full company profile